Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant and modified allergens: the U.S. perspective.

Ronald L Rabin1

  • 1US Food and Drug Administration, Center for Biologics Evaluation, Rockville, MD 20852, USA.

Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt Fur Sera Und Impfstoffe) Zu Frankfurt A.M
|March 31, 2007
PubMed
Summary

To ensure product safety and efficacy, modifications require scientific validation. This includes demonstrating reduced allergenicity, confirmed potency through clinical and animal studies, and assessing biochemical and biological stability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics approach to evaluating personalized biomarkers of allergen immunotherapy.

The Journal of allergy and clinical immunology·2025
Same author

Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.

The Journal of allergy and clinical immunology·2025
Same author

A human monoclonal antibody based immunoenzymetric assay to measure Fel d 1 concentrations in cat hair and pelt allergenic extracts.

Frontiers in allergy·2024
Same author

The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts.

Current allergy and asthma reports·2024
Same author

An enhanced three-stage design with trend analysis for allergen immunotherapy trials.

PloS one·2023
Same author

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.

Vaccine·2023

Area of Science:

  • Immunology
  • Biotechnology
  • Regulatory Science

Background:

  • Allergenicity and antigenicity (potency) are distinct properties.
  • Regulatory requirements necessitate rigorous scientific justification for product modifications.

Purpose of the Study:

  • To outline the scientific criteria for justifying modifications in products where allergenicity and antigenicity are no longer equivalent.
  • To emphasize the need for comprehensive validation of product safety and efficacy.

Main Methods:

  • Standardized methods for demonstrating loss of allergenicity.
  • Animal and clinical studies to confirm potency.
  • Assessment of surrogate markers for clinical efficacy.
  • Evaluation of biochemical and biological stability.

Related Experiment Videos

Main Results:

  • A clear distinction between allergenicity and potency is crucial.
  • Standardized methods are available to assess allergenicity reduction.
  • Potency requires robust validation through in vivo and in vitro studies.
  • Biochemical and biological stability are key indicators of product integrity.

Conclusions:

  • Product modifications demand a multi-faceted scientific approach.
  • Demonstrating reduced allergenicity and confirmed potency is essential for regulatory approval.
  • Comprehensive stability assessments are integral to ensuring product safety and efficacy.